Digest Network Come funziona
Network
/
Società
Ta
Non verificato

Takeda Pharmaceutical Company Limited

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

50 comunicati stampa

Guarda tutti i comunicati
11/06/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Igiene alimentare
Medicina - Varie
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
09/06/2026
Industria
Salute
Igiene alimentare
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
13/05/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Titoli e azioni
Biotecnologia
Farmaceutica
Salute
Oncologia
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
04/05/2026
Industria
Salute
Scienza
Farmaceutica
Medicina - Varie
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
28/03/2026
Eventi
Industria
Web e Social Network
Telefonia e Varie
Salute
Medicina - Varie
Sanità
Scienza
Farmaceutica
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
02/03/2026
Industria
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Farmaceutica
Biotecnologia
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
19/02/2026
Industria
Salute
Scienza
Farmaceutica
Medicina - Varie
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
10/02/2026
Industria
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
29/01/2026
Biotecnologia
Farmaceutica
Salute
Oncologia
Mercato azionario
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
22/01/2026
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0